Follow up of BL/LL patients on a slightly modified WHO regimen of multidrug therapy.
56 lepromatous leprosy patients with an initial average BI of 4.45 were administered once a month 600 mg of Rifampicin, 100 mg of Clofazimine on alternate days and 100 mg of Dapsone daily. None of these patients became smear negative in 2 years, and the same regimen was continued further. Two patients have become negative in 3 years and treatment has been stopped in them. The study indicates that highly bacilliferous LL/BL patients are likely to need 3 years or more of MDT for achieving bacterial negativity.
D000293:Adolescent; D000328:Adult; D002991:Clofazimine / Q000008:administration & dosage / Q000627:therapeutic use*; D003622:Dapsone / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007918:Leprosy / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use*
D003622:Dapsone; D002991:Clofazimine; D012293:Rifampin